• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

Japan studying giving third COVID-19 shots next year

firstwordpharmaAugust 09, 2021

Tag: COVID-19 , Vaccine , Moderna

Japan has begun a study on whether it should administer third doses of COVID-19 vaccines next year, as reported The Japan Times.

The government will proceed with the study while trying to secure the supply of at least 200 million doses next year, officials said.

Japan studying giving third COVID-19 shots next year

Taro Kono, the minister in charge of vaccination efforts, has said that Japan "will likely administer next year" third doses of the COVID-19 vaccine.

In July, the government struck a contract to receive an additional 50 million doses of Moderna's vaccine from the beginning of 2022, and discussions are under way to secure 150 million doses of the vaccine developed by Novavax starting in early 2022.


Previous:FDA to allow export of certain lots of AstraZeneca COVID-19 vaccine made at Baltimore plant

Next:JCVI ‘largely opposed’ to Covid vaccination for children under 16

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Japan studying giving third COVID-19 shots next year | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Inactivated flu vaccine

Inactivated flu vaccine
Meningococcal Group A&C Polysaccharide Conjugate Vaccine

Meningococcal Group A&C Polysaccharide Conjugate Vaccine
Hualan Quadrivalent Influenza Vaccine

Hualan Quadrivalent Influenza Vaccine
Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine

Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine
WHO-PQ Influenza Vaccine

WHO-PQ Influenza Vaccine
Inactivated Influenza Vaccine (Split virion)with stable quality

Inactivated Influenza Vaccine (Split virion)with stable quality
H7N9 Inactivated Influenza Vaccine by hualan biological

H7N9 Inactivated Influenza Vaccine by hualan biological
hualan-trivalent flu vaccine

hualan-trivalent flu vaccine
Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine
Influenza Vaccine in Syringe of Hualan Bio

Influenza Vaccine in Syringe of Hualan Bio

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service